Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

EXPLAINED: 5 | Rare Historical Photos

Given enhanced healthcare spending, the growing frequency of chronic diseases, government support, and rapid digital transformation, the biotech industry appears to have favorable prospects. Therefore, fundamentally strong biotech stocks Vertex Pharmaceuticals (VRTX), Innoviva (INVA), and Acorda Therapeutics, Inc. (ACOR) could be ideal additions to your portfolio this week. Read more….

StockNews.com

3 Biotech Stocks to Buy to Help the Health of Your Portfolio

Amid the dynamic biotech landscape, the sector is set to witness substantial growth fueled by multiple advancements. Hence, fundamentally strong biotech stocks ANI Pharmaceuticals (ANIP), Exelixis (EXEL), and Entrada Therapeutics (TRDA) might be solid investments now. Read more….

StockNews.com

3 Biotech Stocks Beating BioMarin Pharmaceutical (BMRN)

Breakthrough developments, the use of advanced technologies, and rising investments in R&D are some of the factors driving the growth of the biotech industry. Although BioMarin Pharmaceutical (BMRN) showcases strong growth prospects, investors could consider buying even better biotech stocks Amgen (AMGN), Jazz Pharmaceuticals (JAZZ), and Vertex Pharmaceuticals (VRTX). Read…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

Biogen (BIIB) Earnings Spotlight: Is the Biotech Stock a Buy or Sell?

Biotech major Biogen (BIIB) will report its third-quarter results on November 8. Its EPS and revenue are expected to decline year-over-year. However, the FDA approvals for new drugs received by the company this year will likely support its long-term growth. Let’s discuss the potential road ahead for the stock….

StockNews.com

November Buy Alert: 3 Biotech Stocks Making Gains

Given the breakthrough developments and the rising need to treat chronic diseases, the biotech industry is well-positioned to generate returns. This might make buying biotech stocks like Organogenesis Holdings (ORGO), Innoviva (INVA), and Amgen (AMGN) a wise decision this November. Read on….

StockNews.com

4 Promising Biotech Stocks for Smart Investment Strategies

The biotechnology industry is flourishing due to the recent strides in drug formulation, technological advancements, and unwavering government support. Given this backdrop, promising biotech stocks United Therapeutics (UTHR), Vertex Pharmaceuticals (VRTX), Jazz Pharmaceuticals (JAZZ), and Gilead Sciences (GILD) present smart investment options to garner significant returns. Read on….

StockNews.com

3 Biotech Stocks With Potential Future Gains

The pharmaceutical industry's inelastic demand provides stability and resilience against economic fluctuations. Moreover, the industry is well positioned to grow steadily thanks to the rising need to treat chronic diseases. Hence, fundamentally sound pharma stocks Shionogi & Co (SGIOY), Exelixis (EXEL), and Jazz Pharmaceuticals (JAZZ) could be ideal buys now.…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Exploring the Upside Potential of 3 Biotech Stocks

Given the breakthrough developments, government support, and rising need to treat chronic diseases, the biotech industry is well-positioned to grow steadily. So, it could be wise to invest in quality biotech stocks Alkermes (ALKS), Amgen (AMGN) and Incyte (INCY). Read on….

StockNews.com

Top 3 Biotech Stocks Leading the Way This October

The biotech industry is well-positioned for strong growth thanks to increasing demand for high-quality treatments for chronic diseases. Given this backdrop, quality biotech stocks Jazz Pharmaceuticals (JAZZ), Amgen (AMGN), and Gilead Sciences (GILD) could be solid buys for October. Read on….

StockNews.com

3 Biotech Stocks Offering Potential for Gains

Solid foothold of personalized medicine, increasing prevalence of chronic diseases, favorable government initiatives, and rapid digital transformation are opening new avenues for biotech companies. Thus, it could be wise to invest in fundamentally sound biotech stocks BioMarin Pharmaceutical (BMRN), Shionogi (SGIOY), and Exelixis (EXEL)for potential gains. Read on….

StockNews.com

Unlocking Biotech's Potential With 3 Stocks to Buy

The biotech industry’s growth is propelled by strong demand for medical support and interventions, favorable government initiatives, and rapid adoption of emerging technologies. Given the industry’s tailwinds, quality biotech stocks Shionogi (SGIOY), United Therapeutics (UTHR), and Corcept Therapeutics (CORT) could be ideal buys now. Read on….

StockNews.com

3 of the Best Stocks in 1 of Wall Street's Worst-Rated Industry

After years of robust growth, the biotech industry has struggled since last year due to several headwinds, including regulatory concerns, inflation, and the Fed’s aggressive rate hikes, which have sucked out speculative capital. Despite currently being one of the poorly-rated industries, investors could consider buying top-biotech stocks Gilead (GILD), Vertex…

StockNews.com

2 Biotech Stocks to Take off Your Watchlist in 2022

Amid the macroeconomic issues and rampant volatility in the market, investor sentiment toward biotech stocks is declining. Many companies in this space are planning layoffs to reduce expenses. Amid the grim backdrop, we think investors should drop fundamentally weak biotech stocks Ginkgo Bioworks Holdings (DNA) and Immunic (IMUX) from their…

StockNews.com

1 Stock That’ll Make You Turn Blue in the Face for Owning

Biotech company bluebird bio (BLUE) received FDA approval for ZYNTEGLO last month, which seems to have boosted its stock price. However, given its bleak profitability and stretched valuations, the stock might be best avoided. Read on….

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

The Worst Biotech Stock to Own in September

Biotech stock Ginkgo Bioworks (DNA) has fallen more than 60% year-to-date. The company has been making some acquisitions recently to aid its growth over the next few years. However, given its weak financials and unfavorable analyst estimates, it may not be wise to invest in this stock now. Continue reading….

StockNews.com

5 Biotech Stocks to Buy and Hold for the Next Decade

The biotech industry seems poised to witness solid growth over the next decade with intensive innovation, breakthrough developments, and growing investments in the sector. So, given analysts’ promising growth outlook for the industry, it could be wise for investors to buy and hold fundamentally solid biotech stocks Vertex Pharmaceuticals (VRTX),…

1 2 3 4 5

People

Dipanjan BanchurSince

722 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the US Food and Drug Administration

80 stories

Amgen Inc

76 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.